Related Experiment Videos
[Pharmacological therapy of erectile dysfunction]
A J Becker1, C G Stief, D Schultheiss
1Urologische Klinik, Medizinische Hochschule Hannover.
Der Urologe. Ausg. A
|October 31, 1998
Summary
Pharmacotherapy for erectile dysfunction (ED) includes oral and local drugs. New treatments are emerging, offering personalized regimens for ED management.
Area of Science:
- Pharmacology
- Urology
Context:
- Erectile dysfunction (ED) pharmacotherapy involves oral and local drug applications.
- Yohimbine is currently the sole listed drug for ED, acting via central alpha-receptor blockade.
Purpose:
- To review current and emerging pharmacotherapies for erectile dysfunction.
- To highlight the mechanisms of action and clinical efficacy of various ED drugs.
Summary:
- Yohimbine demonstrates significant efficacy compared to placebo.
- Centrally acting agents like Apomorphine show promise, while peripherally acting Sildenafil (a phosphodiesterase-V inhibitor) has proven effective in broad clinical studies.
- Local treatments include intraurethral MUSE and intracavernous prostaglandin E1 (PGE1).
Impact:
- The development of diverse drugs with varied mechanisms and applications facilitates tailored ED treatment regimens.
- Future pharmacological advancements aim for individualized patient management strategies.